H. pylori infection in gastrointestinal cancer: impact on the development, prognosis, and effectiveness of anticancer therapy. Literature review

Study Objective: to provide an overview of current scientific data on the impact of H. pylori infection and eradication therapy on the development, clinical course and treatment outcomes of gastrointestinal cancer.

Material and Methods. A search of Russian and English-language literature sources published in various databases (MedLine, Pubmed, Scopus, The Cochrane Library, and Russian Science Citation Index) between 2004 and 2025 was conducted. Fifty-three available scientific publications were analyzed, including 5 Russian and 48 foreign publications, including 41 articles, 10 meta-analyses, and 2 retrospective studies.

Results. An analysis of scientific papers showed that H. pylori infection significantly worsened treatment outcomes and survival in patients with already diagnosed gastric cancer. Literature data demonstrate a positive impact of H. pylori eradication on survival in both early and advanced gastric cancer. In addition to being a major risk factor for stomach cancer, H. pylori infection is also associated with an increased risk of colorectal cancer, esophageal adenocarcinoma, pancreatic cancer, and biliary tract cancer. Furthermore, H. pylori infection impacts the effectiveness of immunotherapy in cancer treatment

Conclusion. H. pylori infection and eradication therapy can influence the development and clinical course of gastrointestinal tumors. Despite the close attention of many scientists to this issue, key questions remain poorly understood.

1. Reshetnyak V.I., Burmistrov A.I., Maev I.V. Helicobacter pylori: Commensal, symbiont or pathogen? World J. Gastroenterol. 2021; 27(7): 545–60. doi: 10.3748/wjg.v27.i7.545

2. Ivashkin V.T., Lapina T.L., Maev I.V., Drapkina O.M., Kozlov R.S., Sheptulin A.A., Trukhmanov A.S., Abdulkhakov S.R., Alekseeva O.P., Alekseenko S.A., Andreev D.N., Bordin D.S., Dekhnich N.N., Klyaritskaya I.L., Korochanskaya N.V., Osipenko M.F., Poluektova E.A., Sarsenbaeva A.S., Simanenkov V.I., Tkachev A.V., Ulyanin A.I., Khlynov I.B., Tsukanov V.V. Clinical Practice Guidelines of Russian Gastroenterological Association, Scientific Society for the Clinical Study of Human Microbiome, Russian Society for the Prevention of Non-Communicable Diseases, Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy for H. pylori Diagnostics and Treatment in Adults. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2022; 32(6): 72–93. (in Russian). doi: 10.22416/1382-4376-2022-32-6-72-93. EDN: QRQFTQ.

3. Marshall B.J., Warren L.R. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984; 1(8390): 1311–15. doi: 10.1016/s0140-6736(84)91816-6.

4. Bordin D.S., Shengelia M.I., Ivanova V.A., Voynova I.N. The history of the discovery of the Helicobacter pylori. Therapeutic Archive. 2022; 94(2): 283–88. (in Russian). doi: 10.26442/00403660.2022.02.201377. EDN: NXTBRY.

5. de Martel C., Georges D., Bray F., Ferlay J., Clifford G.M. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health. 2020; 8(2): e180–e190. doi: 10.1016/S2214109X(19)30488-7.

6. Salvatori S., Marafini I., Laudisi F., Monteleone G., Stolfi C. Helicobacter pylori and Gastric Cancer: Pathogenetic Mechanisms. Int. J. Mol. Sci. 2023; 24(3): 2895. doi: 10.3390/ijms24032895.

7. Hoft S.G., Noto C.N., DiPaolo R.J. Two Distinct Etiologies of Gastric Cancer: Infection and Autoimmunity. Front Cell Dev Biol. 2021; 9: 752346. doi: 10.3389/fcell.2021.752346.

8. Palrasu M., Zaika E., El-Rifai W., Que J., Zaika A.I. Role of Bacterial and Viral Pathogens in Gastric Carcinogenesis. Cancers (Basel). 2021; 13(8): 1878. doi: 10.3390/cancers13081878.

9. Исаева Г.Ш., Валиева Р.И. Биологические свойства и вирулентность Helicobacter pylori. Клиническая микробиология и антимикробная химиотерапия. 2018; 20(1): 14–23. [Isaeva G.Sh., Valieva R.I. Biological characteristics and virulence of Helicobacter pylori. Clinical microbiology and antimicrobial chemotherapy. 2018; 20(1): 14–23. (in Russian). EDN: UOGXEB.

10. Hatakeyama M. Malignant Helicobacter pylori-associated diseases: Gastric cancer and MALT lymphoma. Adv. Exp. Med. Biol. 2019; 1149: 135–49. doi: 10.1007/5584_2019_363.

11. Hansen L.M., Dekalb D.J., Cai L.P., Solnick J.V. Identification of Pathogenicity Island Genes Associated with Loss of Type IV Secretion Function during Murine Infection with Helicobacter pylori. Infect Immun. 2020; 88(6): e00801–19. doi: 10.1128/IAI.00801-19.

12. Yamaoka Y., Saruuljavkhlan B., Alfaray R.I., Linz B. Pathogenomics of Helicobacter pylori. Curr Top Microbiol Immunol. 2023; 444: 117–55. doi: 10.1007/978-3-031-47331-9_5.

13. Ansari S., Yamaoka Y. Helicobacter pylori Virulence Factors Exploiting Gastric Colonization and its Pathogenicity. Toxins (Basel). 2019; 11(11): 677. doi: 10.3390/toxins11110677.

14. Toyoshima O., Nishizawa T., Koike K. Endoscopic Kyoto classification of Helicobacter pylori infection and gastric cancer risk diagnosis. World J. Gastroenterol. 2020; 26(5): 466–77. doi: 10.3748/wjg.v26.i5.466.

15. Ivashkin V.T., Mayev I.V., Kaprin A.D., Agapov M.Yu., Andreev D.N., Vodoleev A.S., Zharkova M.Yu., Korolev M.P., Kucheryavyi Yu.A., Lapina T.L., Mayevskaya M.V., Okhlobystin A.V., Pavlov Ch.S., Paraskevova A.V., Pirogov S.S., Poluektova E.A., Rumyantseva D.E., Trukhmanov A.S., Tsarkov P.V., Sheptulin A.A., Shifrin O.S. Early Detection of Oncological Diseases of the Digestive System (Guidelines of the Russian Gastroenterological Association and the Russian Association of Oncologists for Primary Care Physicians). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2019; 29(5): 53–74. (in Russian). doi: 10.22416/1382-4376-2019-29-5-53-74. EDN: XYHWQO.

16. Fukase K., Kato M., Kikuchi S., Inoue K., Uemura N., Okamoto S., Terao S., Amagai K., Hayashi S., Asaka M.. Japan Gast Study Group. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet. 2008; 372(9636): 392–97. doi: 10.1016/S0140-6736(08)61159-9.

17. Choi I.J., Kook M.C., Kim Y.I., Cho S.J., Lee J.Y., Kim C.G., Park B., Nam B.H. Helicobacter pylori Therapy for the Prevention of Metachronous Gastric Cancer. N Engl J Med. 2018; 378(12): 1085–95. doi: 10.1056/NEJMoa1708423.

18. Zhao Z., Zhang R., Chen G., Nie M., Zhang F., Chen X., Lin J., Chen Z., Lin F., Wei C., Zheng Z., Ruan S., Huang B., Chen Y., Nie R. Anti-Helicobacter pylori Treatment in Patients With Gastric Cancer After Radical Gastrectomy. JAMA Netw Open. 2024; 7(3): e243812. doi: 10.1001/jamanetworkopen.2024.3812.

19. Kiselev N.M., Klimin S.A., Kolesnik Ya.I., Kokorin R.S., Ashimov E.A., Elagina V.Yu., Shumskaya I.S., Zagainov V.E., Gamayunov S.V. Perioperative chemotherapy and morphological response in the treatment of gastric cancer. Modern Oncology. 2024; 26(3): 276–83. (in Russian).]. doi: 10.26442/18151434.2024.3.202978. EDN: LWZBVP.

20. Zhong B., Xiong Z., Zheng J., Mohamed S.A, Sun J., Huang D., Deng Z., Guo J., Peng J., Wang H., Lian L. Impact of Helicobacter pylori infection on neoadjuvant chemotherapy in locally advanced gastric cancer: a retrospective analysis. BMC Cancer. 2025; 25(1): 157. doi: 10.1186/s12885-025-13494-5.

21. Magahis P.T., Maron S.B., Cowzer D., King S., Schattner M., Janjigian Y., Faleck D., Laszkowska M. Impact of Helicobacter pylori infection status on outcomes among patients with advanced gastric cancer treated with immune checkpoint inhibitors. J Immunother Cancer. 2023; 11(10): e007699. doi: 10.1136/jitc-2023-007699.

22. Jia Z., Zheng M., Jiang J., Cao D., Wu Y., Zhang Y., Fu Y., Cao X. Positive H. pylori status predicts better prognosis of non-cardiac gastric cancer patients: results from cohort study and meta-analysis. BMC Cancer. 2022; 22(1): 155. doi: 10.1186/s12885-022-09222-y.

23. Engelsberger V., Gerhard M., Mejías-Luque R. Effects of Helicobacter pylori infection on intestinal microbiota, immunity and colorectal cancer risk. Front Cell Infect Microbiol. 2024; 14: 1339750. doi: 10.3389/fcimb.2024.1339750

24. Hu K.C., Wu M.S., Chu C.H., Wang H.Y., Lin S.C., Liu C.C., Su T.H., Liao W.C., Chen C.L., Liu C.J., Shih S.C. Decreased Colorectal Adenoma Risk After Helicobacter pylori Eradication: A Retrospective Cohort Study. Clin Infect Dis. 2019; 68(12): 2105–13. doi: 10.1093/cid/ ciy591.

25. Guo C.G., Zhang F., Jiang F., Wang L., Chen Y., Zhang W., Zhou A., Zhang S., Leung W.K. Long-term effect of Helicobacter pylori eradication on colorectal cancer incidences. Therap Adv Gastroenterol. 2023; 16: 17562848231170943. doi: 10.1177/17562848231170943.

26. Gao H., Li L., Zhang C., Tu J., Geng X., Wang J., Zhou X., Jing J., Pan W. Systematic Review with Meta-analysis: Association of Helicobacter pylori Infection with Esophageal Cancer. Gastroenterol Res Pract. 2019; 2019: 1953497. doi: 10.1155/2019/1953497.

27. Nie S., Chen T., Yang X., Huai P., Lu M. Association of Helicobacter pylori infection with esophageal adenocarcinoma and squamous cell carcinoma: a meta-analysis. Dis Esophagus. 2014; 27(7): 645–53. doi: 10.1111/dote.12194.

28. Xie F.J., Zhang Y.P., Zheng Q.Q., Jin H.C., Wang F.L., Chen M., Shao L., Zou D.H., Yu X.M., Mao W.M. Helicobacter pylori infection and esophageal cancer risk: an updated meta-analysis. World J Gastroenterol. 2013; 19(36): 6098–107. doi: 10.3748/wjg.v19.i36.6098.

29. Islami F., Kamangar F. Helicobacter pylori and esophageal cancer risk: a meta-analysis. Cancer Prev Res (Phila). 2008; 1(5): 329–38. doi: 10.1158/1940-6207.CAPR-08-0109.

30. Zhuo X., Zhang Y., Wang Y., Zhuo W., Zhu Y., Zhang X.. Helicobacter pylori infection and oesophageal cancer risk: association studies via evidence-based meta-analyses. Clin Oncol (R Coll Radiol). 2008; 20(10): 757–62. doi: 10.1016/j.clon.2008.07.005.

31. Rokkas T., Pistiolas D., Sechopoulos P., Robotis I., Margantinis G. Relationship between Helicobacter pylori infection and esophageal neoplasia: a meta-analysis. Clin Gastroenterol Hepatol. 2007; 5(12): 1413–7, 1417.e1–2. doi: 10.1016/j.cgh.2007.08.010.

32. Xie T., Cui X., Zheng H., Chen D., He L., Jiang B. Metaanalysis: eradication of Helicobacter pylori infection is associated with the development of endoscopic gastroesophageal reflux disease. Eur J Gastroenterol Hepatol. 2013; 25(10): 1195–205. doi: 10.1097/MEG.0b013e328363e2c7.

33. Kotta A.S., Kelling A.S., Corleto K.A., Sun Y., Giles E.D. Ghrelin and Cancer: Examining the Roles of the Ghrelin Axis in Tumor Growth and Progression. Biomolecules. 2022; 2(4): 483. doi: 10.3390/biom12040483.

34. Bhatt A., Zaidi H.M., Maitra R., Goel S. Infectious Agents and Esophageal Cancer: A Comprehensive Review. Cancers (Basel). 2025; 17(7): 1248. doi: 10.3390/cancers17071248.

35. Hu H.M., Kuo C.H., Lee C.H., Wu I.C., Lee K.W., Lee J.M., Goan Y.G., Chou S.H., Kao E.L., Wu M.T., Wu D.C. Polymorphism in COX-2 modifies the inverse association between Helicobacter pylori seropositivity and esophageal squamous cell carcinoma risk in Taiwan: a case control study. BMC Gastroenterol. 2009; 9: 37. doi: 10.1186/1471230X-9-37.

36. Maity R., Dhali A., Biswas J. Is Helicobacter pylori infection protective against esophageal cancer? World J Gastroenterol. 2024; 30(38): 4168–4174. doi: 10.3748/wjg.v30.i38.4168.

37. Wiklund A.K., Santoni G. Yan J., Radkiewicz C., Xie S., Birgisson H., Ness-Jensen E., von Euler-Chelpin M., Kauppila J.H., Lagergren J. Risk of Esophageal Adenocarcinoma After Helicobacter pylori Eradication Treatment in a Population-Based Multinational Cohort Study. Gastroenterology. 2024; 167(3): 485–92.e3. doi: 10.1053/j.gastro.2024.03.016.

38. Kolesnikova E.A., Bodunova N.A., Danishevich A.M., Nikiforova E.S., Shatalov P.A., Shumskaya I.S., Malinina P.A., Gamayunov S.V., Kuchin D.M., Kiselyov N.M., Zagainov V.E. Spectrum mutations in the genes of hereditary tumor syndromes in pancreatic cancer. Oncology Bulletin of the Volga Region. 2023; 14(4): 49–56. (in Russian). doi: 10.32000/2078-1466-2023-4-49-56. EDN: BGEEAW.

39. Xu W., Zhou X., Yin M., Gao J., Weng Z., Xu C. The relationship between Helicobacter pylori and pancreatic cancer: a meta-analysis. Transl Cancer Res. 2022; 11(8): 2810–22. doi: 10.21037/tcr-21-2803.

40. Yadav D., Lowenfels A.B. The epidemiology of pancreatitis and pancreatic cancer. Gastroenterology. 2013; 144(6): 1252–61. doi: 10.1053/j.gastro.2013.01.068.

41. Yu J., Yang P., Qin X., Li C., Lv Y., Wang X. Impact of smoking on the eradication of Helicobacter pylori. Helicobacter. 2022; 27(1): e12860. doi: 10.1111/hel.12860.

42. Wang Y., Zhang F.C., Wang Y.J. Helicobacter pylori and pancreatic cancer risk: a metaanalysis based on 2,049 cases and 2,861 controls. Asian Pac J Cancer Prev. 2014; 15(11): 4449–54. doi: 10.7314/apjcp.2014.15.11.4449.

43. Cherif S., Bouriat K., Rais H., Elantri S., Amine A. Helicobacter pylori and Biliary Tract Cancers: A Meta-Analysis. Canad J Infec Dis Med Microbiol. 2020 (45): 1–7. doi: 10.1155/2020/9287157.

44. Zhong X., Zheng H., Zhao S., Wang Z., Su Y., Zhong K., Wang M., Shi Y. Effects and mechanisms of Helicobacter pylori on cancers development and immunotherapy. Front Immunol. 2024; 15: 1469096. doi: 10.3389/fimmu.2024.1469096.

45. Magahis P.T., Maron S.B., Cowzer D., King S., Schattner M., Janjigian Y., Faleck D., Laszkowska M. Impact of Helicobacter pylori infection status on outcomes among patients with advanced gastric cancer treated with immune checkpoint inhibitors. J Immunother Cancer. 2023; 11(10): e007699. doi: 10.1136/jitc-2023-007699.

46. Che H., Xiong Q., Ma J., Chen S., Wu H., Xu H., Hou B.. Association of Helicobacter pylori infection with survival outcomes in advanced gastric cancer patients treated with immune checkpoint inhibitors. BMC Cancer. 2022; 22(1): 904. doi: 10.1186/s12885-022-10004-9.

47. Zhang M.J., Chen D.S., Li S., Chen L, Qi Y.X., Zhang C.J.. Helicobacter pylori infection as a potential favorable factor for immune checkpoint inhibitor therapy for gastric cancer. Invest New Drugs. 2021; 39(5): 1436–38. doi: 10.1007/s10637-021-01122-5.

48. Shitara K., van Cutsem E., Bang Y.J., Fuchs C., Wyrwicz L., Lee K.W., Kudaba I., Garrido M., Chung H.C., Lee J., Castro H.R., Mansoor W., Braghiroli M.I., Karaseva N., Caglevic C., Villanueva L., Goekkurt E., Satake H., Enzinger P., Alsina M., Benson A., Chao J., Ko A.H., Wainberg Z.A., Kher U., Shah S., Kang S.P., Tabernero J. Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020; 6(10): 1571–80. doi: 10.1001/jamaoncol.2020.3370.

49. Lee K.W., van Cutsem E., Bang Y.J., Fuchs C.S., Kudaba I., Garrido M., Chung H.C., Lee J., Castro H.R., Chao J., Wainberg Z.A., Cao Z.A., Aurora-Garg D., Kobie J., Cristescu R., Bhagia P., Shah S., Tabernero J., Shitara K., Wyrwicz L. Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study. Clin Cancer Res. 2022; 28(16): 3489–98. doi: 10.1158/1078-0432.CCR-22-0121.

50. Zhu Y., Zhu F., Ba H., Chen J., Bian X. Helicobacter pylori infection and pd-L1 expression in gastric cancer: A meta-analysis. Eur J Clin Invest. 2023; 53(2): e13880. doi: 10.1111/eci.13880.

51. Jia K., Chen Y., Xie Y., Wang X., Hu Y., Sun Y., Cao Y., Zhang L., Wang Y., Wang Z., Lu Z., Li J., Zhang X., Shen L. Helicobacter pylori and immunotherapy for gastrointestinal cancer. Innovation (Camb). 2024; 5(2): 100561. doi: 10.1016/j.xinn.2023.100561.

52. Oster P., Vaillant L., Riva E., McMillan B., Begka C., Truntzer C., Richard C., Leblond M.M., Messaoudene M., Machremi E., Limagne E., Ghiringhelli F., Routy B., Verdeil G., Velin D. Helicobacter pylori infection has a detrimental impact on the efficacy of cancer immunotherapies. Gut. 2022; 71(3): 457–66. doi: 10.1136/gutjnl-2020-323392.

53. Tonneau M., Nolin-Lapalme A., Kazandjian S., Auclin E., Panasci J., Benlaifaoui M., Ponce M., Al-Saleh A., Belkaid W., Naimi S., Mihalcioiu C., Watson I., Bouin M., Miller W., Hudson M., Wong M.K., Pezo R.C., Turcotte S., Bélanger K., Jamal R., Oster P., Velin D., Richard C., Messaoudene M., Elkrief A., Routy B. Helicobacter pylori serology is associated with worse overall survival in patients with melanoma treated with immune checkpoint inhibitors. Oncoimmunology. 2022; 11(1): 2096535. doi: 10.1080/2162402X.2022.2096535.